SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Nectar Lifesciences - Quaterly Results

14 Aug 2025 Evaluate
The sales for the June 2025 quarter moved down to Rs. 2806.71 millions as compared to Rs. 3593.00 millions during the year-ago period.The Net Loss for the quarter ended June 2025 is Rs. -632.32 millions as compared to Net Profit of Rs. 29.69 millions of corresponding quarter ended June 2024Operating profit Margin for the quarter ended June 2025 slipped to -615.45% as compared to 403.54% of corresponding quarter ended June 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 2806.71 3593.00 -21.88 2806.71 3593.00 -21.88 16730.75 16856.32 -0.74
Other Income 3.50 5.51 -36.48 3.50 5.51 -36.48 18.91 130.30 -85.49
PBIDT -615.45 403.54 -252.51 -615.45 403.54 -252.51 -245.67 1661.35 -114.79
Interest 186.95 199.77 -6.42 186.95 199.77 -6.42 745.78 871.42 -14.42
PBDT -802.40 203.77 -493.78 -802.40 203.77 -493.78 -991.45 789.93 -225.51
Depreciation 165.16 154.60 6.83 165.16 154.60 6.83 623.89 607.18 2.75
PBT -967.56 49.17 -2067.79 -967.56 49.17 -2067.79 -1615.34 182.75 -983.91
TAX -335.24 19.48 -1820.94 -335.24 19.48 -1820.94 -478.53 132.74 -460.50
Deferred Tax -335.24 19.48 -1820.94 -335.24 19.48 -1820.94 -478.53 132.74 -460.50
PAT -632.32 29.69 -2229.74 -632.32 29.69 -2229.74 -1136.81 50.01 -2373.17
Equity 224.26 224.26 0.00 224.26 224.26 0.00 224.26 224.26 0.00
PBIDTM(%) -18.09 9.65 -287.34 -21.93 11.23 -295.24 -1.29 8.62 -114.91

Nectar Lifesciences Share Price

12.66 0.25 (2.01%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×